It was observed that patients with lung cancer had a higher percentage of CD4+IL-22+IL-17− cells, when compared to healthy controls (controls vs. lung cancer patients: 1.93 ± 0.25% vs. 6.06 ± 0.65%, P < 0.0001; Figure 1). Here, IL22 is linked to lung carcinoma.